(Q44723860)

English

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maria Di Bartolomeo

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

object named as

Andrea Bonetti

8

0 references

Graziella Pinotti

7

object named as

Graziella Pinotti

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

author name string

Emilio Bajetta

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Antonio Cassata

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Salvatore Artale

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sergio Frustaci

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Ignazio Carreca

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Guido Biasco

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Luigi Bonaglia

11

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Giovanni Marini

12

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Antonio Iannelli

13

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Diego Cortinovis

14

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Ermina Ferrario

15

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Elena Beretta

16

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Antonio Lambiase

17

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Roberto Buzzoni

18

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Italian Trials in Medical Oncology (I.T.M.O.) Group

19

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

100

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

279-287

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

National Cancer Institute Clinical Trials Program in Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fluoropyrimidines in the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan in the treatment of colorectal cancer: clinical overview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

A study of quality of life in cancer patients receiving palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11910

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11910

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44723860&oldid=2034612457"